BACKGROUND: Recent studies have shown an increased incidence of primary graft dysfunction (PGD) in patients treated with amiodarone prior to orthotopic heart transplant (OHT). We hypothesized that discontinuation of amiodarone before OHT may lower the incidence of severe PGD. METHODS: This was a single-center retrospective study of 381 adult OHT recipients between January 2010 and June 2017. Within 6 months prior to OHT, 197 did not receive amiodarone (Group 1), 142 continued amiodarone to OHT (Group 2), and 42 had amiodarone treatment discontinued before OHT (Group 3). RESULTS: 53 (13.9%) participants developed severe PGD, 13 (6.6%) of which were in Group 1, 36 (25.4%) were in Group 2, and 4 (9.5%) were in Group 3 (P < .001). Multivariable analysis revealed continued amiodarone treatment to OHT (Group 2; OR, 3.70; 95% CI, 1.26-10.88; P = .018) to be an independent risk factor for the development of severe PGD when Group 1 served as the reference group. Moreover, patients in Group 3 had no difference in the risk of severe PGD (OR = 0.416, 95% CI = 0.08-2.15; P = .296). CONCLUSION: We found that discontinuing amiodarone treatment prior to OHT resulted a lower incidence of severe PGD.
BACKGROUND: Recent studies have shown an increased incidence of primary graft dysfunction (PGD) in patients treated with amiodarone prior to orthotopic heart transplant (OHT). We hypothesized that discontinuation of amiodarone before OHT may lower the incidence of severe PGD. METHODS: This was a single-center retrospective study of 381 adult OHT recipients between January 2010 and June 2017. Within 6 months prior to OHT, 197 did not receive amiodarone (Group 1), 142 continued amiodarone to OHT (Group 2), and 42 had amiodarone treatment discontinued before OHT (Group 3). RESULTS: 53 (13.9%) participants developed severe PGD, 13 (6.6%) of which were in Group 1, 36 (25.4%) were in Group 2, and 4 (9.5%) were in Group 3 (P < .001). Multivariable analysis revealed continued amiodarone treatment to OHT (Group 2; OR, 3.70; 95% CI, 1.26-10.88; P = .018) to be an independent risk factor for the development of severe PGD when Group 1 served as the reference group. Moreover, patients in Group 3 had no difference in the risk of severe PGD (OR = 0.416, 95% CI = 0.08-2.15; P = .296). CONCLUSION: We found that discontinuing amiodarone treatment prior to OHT resulted a lower incidence of severe PGD.
Authors: Erika Hrudikova Vyskocilova; Milan Grundmann; Jana Duricova; Ivana Kacirova Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2017-03-31 Impact factor: 1.245
Authors: Nora Goldschlager; Andrew E Epstein; Gerald V Naccarelli; Brian Olshansky; Bramah Singh; Harold R Collard; Elizabeth Murphy Journal: Heart Rhythm Date: 2007-07-20 Impact factor: 6.343
Authors: Andrew E Epstein; Brian Olshansky; Gerald V Naccarelli; John I Kennedy; Elizabeth J Murphy; Nora Goldschlager Journal: Am J Med Date: 2015-11-11 Impact factor: 4.965
Authors: Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Bastian Schmack; Christian Erbel; Christian A Gleissner; Mohammadreza Akhavanpoor; Lutz Frankenstein; Fabrice F Darche; Patrick A Schweizer; Dierk Thomas; Philipp Ehlermann; Tom Bruckner; Hugo A Katus; Andreas O Doesch Journal: Drug Des Devel Ther Date: 2016-02-16 Impact factor: 4.162